文献速递造血干细胞移植与细胞治疗

血液中独特的免疫特征可区分治疗难治性与治疗反应性急性移植物抗宿主病

A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease.
PubMed 文献 · Blood · 2023-01-01

该研究采用质谱流式技术(CyTOF)分析接受一线免疫抑制治疗或联合间充质干细胞(MSC)二线治疗的严重(III-IV级)急性移植物抗宿主病(aGVHD)患儿外周血髓系与淋系细胞,并与无aGVHD移植患儿及年龄匹配健康对照比较。aGVHD发作与CD11b+CD163+髓系细胞出现及TCRγδ+等活化T细胞群相关;对一、二线治疗均难治的患者早期出现IgM presumable class switched、浆母细胞及2个CD11b-树突状细胞亚群,且皮肤或肠道归巢受体效应与调节性T细胞比例持续偏高,而治疗反应者该频率下降。

要点

  • aGVHD发作时外周血出现CD11b+CD163+髓系细胞并浸润皮肤和胃肠道。
  • 同一血样中可见表达活化标志及皮肤/肠道归巢趋化因子受体的TCRγδ+等T细胞群。
  • 难治患者早期出现IgM presumable class switched、浆母细胞及2个CD11b-树突状细胞亚群,皮肤或肠道归巢效应与调节性T细胞比例持续偏高,治疗反应者则下降。

核心结论

  • aGVHD发作时淋系与髓系均被触发,高通量免疫细胞谱分析对临床反应评估有附加价值,可能有助于严重aGVHD管理的及时决策。

研究设计与样本

  • 应用质谱流式技术(CyTOF)分析接受单纯免疫抑制药物一线治疗或联合间充质干细胞(MSC)二线治疗的严重(III-IV级)aGVHD患儿循环髓系与淋系细胞,并与无aGVHD移植患儿及年龄匹配健康对照的CyTOF数据比较。

主要发现

  • aGVHD发作与外周血CD11b+CD163+髓系细胞出现及其在皮肤和胃肠道积聚相关。
  • 同一血样中可见表达活化标志和皮肤/胃肠道归巢趋化因子受体的TCRγδ+等T细胞群,CXCR3+ T细胞过夜刺激后释放促炎因子。
  • 对一、二线(MSC为基础)治疗均难治的患者早期出现IgM presumable class switched、浆母细胞及2个CD11b-树突状细胞亚群。
  • 难治患者皮肤或肠道归巢受体效应与调节性T细胞比例随时间持续偏高,而治疗反应者该频率下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGVHD) is an immune cell‒driven, potentially lethal complication of allogeneic hematopoietic stem cell transplantation affecting diverse organs, including the skin, liver, and gastrointestinal (GI) tract. We applied mass cytometry (CyTOF) to dissect circulating myeloid and lymphoid cells in children with severe (grade III-IV) aGVHD treated with immune suppressive drugs alone (first-line therapy) or in combination with mesenchymal stromal cells (MSCs; second-line therapy). These results were compared with CyTOF data generated in children who underwent transplantation with no aGVHD or age-matched healthy control participants. Onset of aGVHD was associated with the appearance of CD11b+CD163+ myeloid cells in the blood and accumulation in the skin and GI tract. Distinct T-cell populations, including TCRγδ+ cells, expressing activation markers and chemokine receptors guiding homing to the skin and GI tract were found in the same blood samples. CXCR3+ T cells released inflammation-promoting factors after overnight stimulation. These results indicate that lymphoid and myeloid compartments are triggered at aGVHD onset. Immunoglobulin M (IgM) presumably class switched, plasmablasts, and 2 distinct CD11b- dendritic cell subsets were other prominent immune populations found early during the course of aGVHD in patients refractory to both first- and second-line (MSC-based) therapy. In these nonresponding patients, effector and regulatory T cells with skin- or gut-homing receptors also remained proportionally high over time, whereas their frequencies declined in therapy responders. Our results underscore the additive value of high-dimensional immune cell profiling for clinical response evaluation, which may assist timely decision-making in the management of severe aGVHD.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. van Halteren AGS, Suwandi JS, Tuit S, et al. A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease. Blood. 2023. PMID: 36044666. doi:10.1182/blood.2022015734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。